J Cancer 2011; 2:350-356. doi:10.7150/jca.2.350


Immunotherapeutic Intervention against Sarcomas

Paolo Pedrazzoli1,4✉, Simona Secondino1, Vittorio Perfetti1, Patrizia Comoli2, Daniela Montagna3

1. SC Oncologia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
2. Onco-ematologia Pediatrica, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
3. Dipartimento di Scienze Pediatriche, Università di Pavia, Pavia, Italy, Fondazione IRCCS Policlinico San Matteo
4. Gruppo Italiano Trapianto di Midollo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO)


Advances in systemic therapy for sarcoma have produced, over the last two decades, relatively short-term benefits for the majority of patient. Among the novel biologic therapeutics that will likely increase our ability to cure human cancer in the years to come, immunotherapy is one of the most promising approaches. While past attempts to use immunotherapy have failed to dramatically shift the paradigm of care for the treatment of patients with sarcoma, major advances in basic and translational research have resulted, in more recent years, in clinical trial activity that is now beginning to generate promising results. However, to move from “proof of principle” to large scale clinical applicability, we need well-designed, multi-institutional clinical trials, along with continuous laboratory research to explore further the immunological characteristics of individual sarcoma subtypes and the consequent tailoring of therapy.

Keywords: Immunotherapy, sarcoma

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Pedrazzoli P, Secondino S, Perfetti V, Comoli P, Montagna D. Immunotherapeutic Intervention against Sarcomas. J Cancer 2011; 2:350-356. doi:10.7150/jca.2.350. Available from http://www.jcancer.org/v02p0350.htm